Session Information
Date: Wednesday, June 22, 2016
Session Title: Parkinson's disease: Cognition
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To study the value of various neuropsychological scales to determine the degree of cognitive dysfunction in patients with posttraumatic subcortical Parkinsonian dementia, during the neuroprotective, antiParkinsonian therapy.
Background: Dementia is a degenerative disorder involving the compromise of multiple domains of cognition. This definition excludes acute confusion of any cause and also chronic focal brain syndromes, in particular the amnesic syndrome.
Methods: The study included 11 patients (6 male and 5 female) who are hospitalized in the neurology department of TMA from the (2013-2014)year, aged 42 to 73 years (middle age 50,2 ± 7,4 years) suffering with posttraumatic subcortical Parkinsonian dementia. To assessment neurological status used brief scale to assessment cognitive status Mini Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA). Patients were divided into 2 groups: the main group consisted of 6 patients with traditional therapy was appointed «Memantin» during the 2 months. The control group consisted of 5 patients who received only conventional therapy without «Memantin».
Results: In the study group patients, who take «Memantin» cognitive function are improved (memory, thinking, comprehension) to 32 % than in the control group. It was found that prior to treatment, patients in the study group took 19.2 on the MMSE, and 20.1 point from the MoCA. Patients in the control group, respectively, 19.6 and 20.4. After treatment, the patients of the main group on the MMSE score increased to 26.4 points, patients in the control group score been 24.1 points. By the MoCA the study group scored 25.2 points, patients in the control group 21.6 points.
Conclusions: 1. The use of scales to determine the cognitive dysfunctions enables to improved identification degree of cognitive dysfunctions. 2. The use of a neuroprotective, antiParkinsonian drug «Memantin» in patients with posttraumatic subcortical Parkinsonian dementia to improved the condition of patients and reduce the severity of the degree of cognitive impairment, frequent in this pathology.
To cite this abstract in AMA style:
R.R. Umarov, N.G. Sokhibnazarov. Treatment and diagnosis with the use of neuropsychological scale in patients with posttraumatic subcortical Parkinsonian dementia [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/treatment-and-diagnosis-with-the-use-of-neuropsychological-scale-in-patients-with-posttraumatic-subcortical-parkinsonian-dementia/. Accessed May 13, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/treatment-and-diagnosis-with-the-use-of-neuropsychological-scale-in-patients-with-posttraumatic-subcortical-parkinsonian-dementia/